サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：インシリコ創薬市場- 世界の産業規模、シェア、動向、機会、予測、2017-2027年
市場調査レポート
商品コード
1321044

インシリコ創薬市場- 世界の産業規模、シェア、動向、機会、予測、2017-2027年

In Silico Drug Discovery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Component, By Workflow, By Software Type, By Technology, By Therapeutic Area, By End User, By Company and By Region
出版日: | 発行: TechSci Research | ページ情報: 英文 117 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

インシリコ創薬市場- 世界の産業規模、シェア、動向、機会、予測、2017-2027年
出版日: 2023年08月01日
発行: TechSci Research
ページ情報: 英文 117 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界のインシリコ創薬市場は、予測期間2023～2027年に目覚ましい成長を遂げると予測されています。

主な要因としては、様々な疾患の新興国市場における増加、クラウド別のアプリケーションの利用増加、技術の広範な開拓などが挙げられ、これらが市場の成長を抑制しています。現在、インシリコ手法は創薬プロセスにおいて不可欠なものとなりつつあります。これは主に、コストと時間を大幅に削減しながら新薬の可能性を特定・発見し、医薬品開発全体の軌道に影響を与えるためです。市場の成長を支えるその他の要因としては、広範な研究開発、さまざまな疾患の流行、多数の臨床試験、医療過誤や再入院率の削減に対する重点の高まり、さまざまな投資、企業間の協力関係の増加、創薬データ量の増加などが挙げられます。

クラウド別・アプリケーションの採用増加

クラウドアプリケーションの利用が増加していることが、インシリコ創薬市場の成長を後押ししています。クラウドコンピューティングにより、製薬研究者は実質的に無限の計算資源を利用できるようになり、コンピューティング環境の拡張や縮小が可能になります。クラウド・コンピューティングは全体的な生産性を向上させるだけでなく、臨床失敗の可能性を最小限に抑えます。例えば2020年には、ブリストル大学の研究者がクラウド別のソリューションを利用して、ADDomerと呼ばれる予防介入の可能性のある物質の構造を解釈することに成功したとされています。

技術の進歩が市場を支える

計算生物学の分野における急速な技術進歩が、インシリコ創薬市場の世界的成長を後押ししています。計算技術は、新規医薬化合物の開発に極めて有効です。技術の進歩により、シーケンシングの様々なステップが簡素化され、得られる結果はより迅速で正確なものとなっています。例えば、2021年、ファイザー社とアマゾン・ウェブ・サービス（AWS）は、新薬の研究、製造、臨床試験のための普及方法を近代化する可能性のある、新しいクラウド別技術の開発で協力することを承認しました。同様に、2022年には、Insilico Medicineとチューリッヒ大学が、InsilicoのダイナミックAI技術を活用して新たなシスチン症治療法を発見するために協力しました。

投資とコラボレーションの増加

様々な疾病の発生件数の増加に伴う創薬開発への多額の投資が、市場の成長を促進しています。例えば、2021年に米国研究製薬工業協会（PhRMA）が発表した報告書によると、バイオ医薬品企業は過去10年間で研究開発に1兆ドル以上を投資しており、その中にはPhRMA加盟業界だけで約910億米ドルを投資した2020年の記録も含まれています。さらに、AIスタートアップ企業が大手研究センターと提携する件数が増加していることも、別の指標を提供する可能性があります。例えば、2017年に開始したGSKとの3,300万ポンドのパートナーシップの一環として、2019年にExscientiaは慢性閉塞性肺疾患の治療をターゲットとしたリード分子を提供しました。

市場プレイヤー

Aragen Life Sciences Pvt.（GVK Biosciences Pvt. Ltd.）、Curia Global, Inc.（Albany Molecular Research Inc.）、Charles River Laboratories International, Inc.、Chemical Computing Group ULC.（CCG）、Collaborative Drug Discovery Inc.（CDD）、e-therapeutics plc.、Dassault Systemes SE、Insilico Medicine, Inc.、Numerate, Inc.、Schrodinger, Inc.などがこの市場で事業を展開している大手企業です。

利用可能なカスタマイズ

TechSciリサーチは、所定の市場データを用いて、企業固有のニーズに応じたカスタマイズを提供します。レポートでは以下のカスタマイズが可能です：

企業情報

  • 追加市場参入企業（最大5社）の詳細分析とプロファイリング

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界のインシリコ創薬市場に与える影響

第5章 顧客の声

第6章 世界のインシリコ創薬市場展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • コンポーネント別（ソフトウェア、ソフトウェア・アズ・ア・サービス、コンサルタント・アズ・ア・サービス）
    • ワークフロー別（創薬、前臨床試験、臨床試験）
    • ソフトウェアタイプ別（分子モデリング・De Novoドラッグデザインソフトウェア、ファーマコフォアモデリングソフトウェア）
    • 技術別（人工知能、グラフィックス・プロセッシング・ユニット、その他）
    • 治療領域別（ヒト免疫不全ウイルス（HIV）、感染症、代謝疾患、腫瘍疾患、その他）
    • エンドユーザー別（バイオテクノロジー・製薬企業、受託研究機関、学術・研究機関、その他）
    • 企業別（2021年）
    • 地域別
  • 市場マップ

第7章 北米のインシリコ創薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • コンポーネント別
    • ワークフロー別
    • ソフトウェアタイプ別
    • 技術別
    • 治療領域別
    • エンドユーザー別
  • 北米国別分析
    • 米国
    • カナダ
    • メキシコ

第8章 欧州のインシリコ創薬市場展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • コンポーネント別
    • ワークフロー別
    • ソフトウェアタイプ別
    • 技術別
    • 治療領域別
    • エンドユーザー別
    • 国別
  • 欧州国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第9章 アジア太平洋のインシリコ創薬市場展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • コンポーネント別
    • ワークフロー別
    • ソフトウェアタイプ別
    • 技術別
    • 治療領域別
    • エンドユーザー別
    • 国別
  • アジア太平洋地域国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第10章 南米のインシリコ創薬市場展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • コンポーネント別
    • ワークフロー別
    • ソフトウェアタイプ別
    • 技術別
    • 治療領域別
    • エンドユーザー別
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第11章 中東・アフリカのインシリコ創薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • コンポーネント別
    • ワークフロー別
    • ソフトウェアタイプ別
    • 技術別
    • 治療領域別
    • エンドユーザー別
    • 国別
  • MEA：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • トルコ
    • エジプト

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場動向と発展

第14章 競合情勢

  • Aragen Life Sciences Pvt. Ltd.（GVK Biosciences Pvt. Ltd.）
  • Curia Global, Inc.（Albany Molecular Research Inc.）
  • Charles River Laboratories International, Inc.
  • Chemical Computing Group ULC.（CCG）
  • Collaborative Drug Discovery Inc.（CDD）
  • e-therapeutics plc.
  • Dassault Systemes SE
  • Insilico Medicine, Inc.
  • Numerate, Inc.
  • Schrodinger, Inc.

第15章 戦略的提言

目次
Product Code: 13007

The global in silico drug discovery market is anticipated to observe impressive growth during the forecast period 2023-2027. The major factors include growing incidences of various diseases, rising use of cloud-based applications, and extensive development in technology, which are curbing the market's growth. Nowadays, in silico methodologies are becoming an essential part of the drug discovery process. This is primarily because of the impact on the whole drug development trajectory, identifying and discovering new potential drugs with a substantial reduction in cost and time. The other factors supporting the market's growth are the extensive research and development, prevalence of various diseases, large number of clinical trials, rising emphasis on reduction in medical errors and readmission rates, various investments, the growing number of collaborations between companies, and rise in the volume of drug discovery data.

Rising Adoption of Cloud-Based Applications

The increasing use of cloud applications is fueling the growth of the in-silico drug discovery market. Cloud computing gives access to pharmaceutical researchers to use virtually infinite computational resources, permitting them to scale up or down their computing environment. Cloud computing has not only enhanced overall productivity but also minimized the chances of clinical failure. For instance, in 2020, researchers at the University of Bristol alleged to have used cloud-based solutions to successfully interpret the structure of a potential preventive intervention called ADDomer.

Technological Advancements Support the Market

Rapid technological advancements in the field of computational biology are bolstering the growth of the in-silico drug discovery market globally. Computational techniques are quite effective in the development of novel pharmaceutical compounds. The advancement in technologies is simplifying the various steps in sequencing, due to which the results obtained are faster and more accurate. For instance, in 2021, Pfizer Inc. and Amazon Web Services (AWS) have approved to work together on developing novel cloud-based technologies that could modernize how new medications are studied, manufactured, and disseminated for clinical trials. Similarly, in 2022, Insilico Medicine and the University of Zurich collaborated to leverage Insilico's dynamic AI technology to discover new cystinosis treatments.

Increasing Investments and Collaborations

Heavy investments in drug discovery and development with rising occurrences of various diseases are propelling the growth of the market. For instance, in 2021, as per a report published by the Pharmaceutical Research and Manufacturers of America (PhRMA), biopharmaceutical companies invested more than a trillion dollars in R&D in the last ten years, including a record year in 2020, when PhRMA member industries alone invested approximately 91 billion USD. Furthermore, the increasing number of partnerships that AI start-ups have with leading research centers may offer an alternative metric. For instance, in 2019, as a part of a £33 million partnership with GSK that commenced in 2017, Exscientia delivered a lead molecule targeted at the treatment of chronic obstructive pulmonary disease.

Market Segmentation

The global in silico drug discovery market is segmented into components, workflow, software type, technology, therapeutic area, end user, and company. Based on components, the market is divided into software, software-as-a-service, and consultancy-as-a-service. Based on workflow, the market is divided into discovery, pre-clinical tests, and clinical trials. Based on the discovery, the market is further segmented into target identification, target validation, and lead discovery. Based on software type, the market is segmented into molecular modeling & de novo drug design software and pharmacophore modeling software. Based on technology, the market is segmented into artificial intelligence, graphics processing unit, and others. Based on therapeutic area, the market is segmented into human immunodeficiency virus (HIV), infectious diseases, metabolic disorders, oncology disorders, and others. Based on end users, the market is divided into biotechnology & pharmaceutical companies, contract research organizations, academic & research organizations, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the extensive technology development in the country.

Market Players

Aragen Life Sciences Pvt. Ltd. (GVK Biosciences Pvt. Ltd.), Curia Global, Inc. (Albany Molecular Research Inc.), Charles River Laboratories International, Inc., Chemical Computing Group ULC. (CCG), Collaborative Drug Discovery Inc. (CDD), e-therapeutics plc., Dassault Systemes SE, Insilico Medicine, Inc., Numerate, Inc., and Schrodinger, Inc. are some of the leading companies operating in the market.

Report Scope

In this report, global in silico drug discovery market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

In Silico Drug Discovery Market, By Component:

  • Software
  • Software-as-a-Service
  • Consultancy-as-a-Service

In Silico Drug Discovery Market, By Workflow:

  • Discovery
    • Target Identification
    • Target Validation
    • Lead Discovery
  • Pre-Clinical Tests
  • Clinical Trials

In Silico Drug Discovery Market, By Software Type:

  • Molecular Modeling & De Novo Drug Design Software
  • Pharmacophore Modeling Software

In Silico Drug Discovery Market, By Technology:

  • Artificial Intelligence
  • Graphics Processing Unit
  • Others

In Silico Drug Discovery Market, By Therapeutic Area:

  • Human Immunodeficiency Virus (HIV)
  • Infectious Diseases
  • Metabolic Disorders
  • Oncology Disorders
  • Others

In Silico Drug Discovery Market, By End User:

  • Biotechnology & Pharmaceutical Companies
  • Contract Research Organizations
  • Academic & Research Organizations
  • Others

In Silico Drug Discovery Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global In Silico Drug Discovery Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global In Silico Drug Discovery Market

5. Voice of Customer

6. Global In Silico Drug Discovery Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
    • 6.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
      • 6.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
    • 6.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
    • 6.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
    • 6.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
    • 6.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
    • 6.2.7. By Company (2021)
    • 6.2.8. By Region
  • 6.3. Market Map

7. North America In Silico Drug Discovery Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
    • 7.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
      • 7.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
    • 7.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
    • 7.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
    • 7.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
    • 7.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
    • 7.2.7. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States In Silico Drug Discovery Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Component
        • 7.3.1.2.2. By Workflow
        • 7.3.1.2.3. By Software Type
        • 7.3.1.2.4. By Technology
        • 7.3.1.2.5. By Therapeutic Area
        • 7.3.1.2.6. By End User
    • 7.3.2. Canada In Silico Drug Discovery Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Component
        • 7.3.2.2.2. By Workflow
        • 7.3.2.2.3. By Software Type
        • 7.3.2.2.4. By Technology
        • 7.3.2.2.5. By Therapeutic Area
        • 7.3.2.2.6. By End User
    • 7.3.3. Mexico In Silico Drug Discovery Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Component
        • 7.3.3.2.2. By Workflow
        • 7.3.3.2.3. By Software Type
        • 7.3.3.2.4. By Technology
        • 7.3.3.2.5. By Therapeutic Area
        • 7.3.3.2.6. By End User

8. Europe In Silico Drug Discovery Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
    • 8.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
      • 8.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
    • 8.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
    • 8.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
    • 8.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
    • 8.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
    • 8.2.7. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France In Silico Drug Discovery Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Component
        • 8.3.1.2.2. By Workflow
        • 8.3.1.2.3. By Software Type
        • 8.3.1.2.4. By Technology
        • 8.3.1.2.5. By Therapeutic Area
        • 8.3.1.2.6. By End User
    • 8.3.2. Germany In Silico Drug Discovery Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Component
        • 8.3.2.2.2. By Workflow
        • 8.3.2.2.3. By Software Type
        • 8.3.2.2.4. By Technology
        • 8.3.2.2.5. By Therapeutic Area
        • 8.3.2.2.6. By End User
    • 8.3.3. United Kingdom In Silico Drug Discovery Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Component
        • 8.3.3.2.2. By Workflow
        • 8.3.3.2.3. By Software Type
        • 8.3.3.2.4. By Technology
        • 8.3.3.2.5. By Therapeutic Area
        • 8.3.3.2.6. By End User
    • 8.3.4. Italy In Silico Drug Discovery Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Component
        • 8.3.4.2.2. By Workflow
        • 8.3.4.2.3. By Software Type
        • 8.3.4.2.4. By Technology
        • 8.3.4.2.5. By Therapeutic Area
        • 8.3.4.2.6. By End User
    • 8.3.5. Spain In Silico Drug Discovery Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Component
        • 8.3.5.2.2. By Workflow
        • 8.3.5.2.3. By Software Type
        • 8.3.5.2.4. By Technology
        • 8.3.5.2.5. By Therapeutic Area
        • 8.3.5.2.6. By End User

9. Asia-Pacific In Silico Drug Discovery Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
    • 9.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
      • 9.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
    • 9.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
    • 9.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
    • 9.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
    • 9.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
    • 9.2.7. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China In Silico Drug Discovery Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Component
        • 9.3.1.2.2. By Workflow
        • 9.3.1.2.3. By Software Type
        • 9.3.1.2.4. By Technology
        • 9.3.1.2.5. By Therapeutic Area
        • 9.3.1.2.6. By End User
    • 9.3.2. India In Silico Drug Discovery Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Component
        • 9.3.2.2.2. By Workflow
        • 9.3.2.2.3. By Software Type
        • 9.3.2.2.4. By Technology
        • 9.3.2.2.5. By Therapeutic Area
        • 9.3.2.2.6. By End User
    • 9.3.3. Japan In Silico Drug Discovery Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Component
        • 9.3.3.2.2. By Workflow
        • 9.3.3.2.3. By Software Type
        • 9.3.3.2.4. By Technology
        • 9.3.3.2.5. By Therapeutic Area
        • 9.3.3.2.6. By End User
    • 9.3.4. South Korea In Silico Drug Discovery Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Component
        • 9.3.4.2.2. By Workflow
        • 9.3.4.2.3. By Software Type
        • 9.3.4.2.4. By Technology
        • 9.3.4.2.5. By Therapeutic Area
        • 9.3.4.2.6. By End User
    • 9.3.5. Australia In Silico Drug Discovery Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Component
        • 9.3.5.2.2. By Workflow
        • 9.3.5.2.3. By Software Type
        • 9.3.5.2.4. By Technology
        • 9.3.5.2.5. By Therapeutic Area
        • 9.3.5.2.6. By End User

10. South America In Silico Drug Discovery Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
    • 10.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
      • 10.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
    • 10.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
    • 10.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
    • 10.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
    • 10.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
    • 10.2.7. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil In Silico Drug Discovery Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Component
        • 10.3.1.2.2. By Workflow
        • 10.3.1.2.3. By Software Type
        • 10.3.1.2.4. By Technology
        • 10.3.1.2.5. By Therapeutic Area
        • 10.3.1.2.6. By End User
    • 10.3.2. Argentina In Silico Drug Discovery Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Component
        • 10.3.2.2.2. By Workflow
        • 10.3.2.2.3. By Software Type
        • 10.3.2.2.4. By Technology
        • 10.3.2.2.5. By Therapeutic Area
        • 10.3.2.2.6. By End User
    • 10.3.3. Colombia In Silico Drug Discovery Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Component
        • 10.3.3.2.2. By Workflow
        • 10.3.3.2.3. By Software Type
        • 10.3.3.2.4. By Technology
        • 10.3.3.2.5. By Therapeutic Area
        • 10.3.3.2.6. By End User

11. Middle East and Africa In Silico Drug Discovery Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
    • 11.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
      • 11.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
    • 11.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
    • 11.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
    • 11.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
    • 11.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
    • 11.2.7. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa In Silico Drug Discovery Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Component
        • 11.3.1.2.2. By Workflow
        • 11.3.1.2.3. By Software Type
        • 11.3.1.2.4. By Technology
        • 11.3.1.2.5. By Therapeutic Area
        • 11.3.1.2.6. By End User
    • 11.3.2. Saudi Arabia In Silico Drug Discovery Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Component
        • 11.3.2.2.2. By Workflow
        • 11.3.2.2.3. By Software Type
        • 11.3.2.2.4. By Technology
        • 11.3.2.2.5. By Therapeutic Area
        • 11.3.2.2.6. By End User
    • 11.3.3. UAE In Silico Drug Discovery Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Component
        • 11.3.3.2.2. By Workflow
        • 11.3.3.2.3. By Software Type
        • 11.3.3.2.4. By Technology
        • 11.3.3.2.5. By Therapeutic Area
        • 11.3.3.2.6. By End User
    • 11.3.4. Turkey In Silico Drug Discovery Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Component
        • 11.3.4.2.2. By Workflow
        • 11.3.4.2.3. By Software Type
        • 11.3.4.2.4. By Technology
        • 11.3.4.2.5. By Therapeutic Area
        • 11.3.4.2.6. By End User
    • 11.3.5. Egypt In Silico Drug Discovery Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Component
        • 11.3.5.2.2. By Workflow
        • 11.3.5.2.3. By Software Type
        • 11.3.5.2.4. By Technology
        • 11.3.5.2.5. By Therapeutic Area
        • 11.3.5.2.6. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Aragen Life Sciences Pvt. Ltd. (GVK Biosciences Pvt. Ltd.)
  • 14.2. Curia Global, Inc. (Albany Molecular Research Inc.)
  • 14.3. Charles River Laboratories International, Inc.
  • 14.4. Chemical Computing Group ULC. (CCG)
  • 14.5. Collaborative Drug Discovery Inc. (CDD)
  • 14.6. e-therapeutics plc.
  • 14.7. Dassault Systemes SE
  • 14.8. Insilico Medicine, Inc.
  • 14.9. Numerate, Inc.
  • 14.10. Schrodinger, Inc.

15. Strategic Recommendations